Establishment and synthesis method of dual-targeting DNA (deoxyribonucleic acid) nano drug-loaded complex
The invention discloses an establishment and synthesis method of a dual-targeting DNA (deoxyribonucleic acid) nano drug-loaded complex. The drug-loaded complex is prepared by the following steps: simultaneously connecting an Aptamer 1 and a natural AS1411 or a chemically modified AS1411 to a DNA tetrahedron in a manner of complementary base pairing, so as to respectively obtain a DNA tetrahedral Aptamer 1-AS1411, a DNA tetrahedral Aptamer 1-AS1411-1, a DNA tetrahedral Aptamer 1-AS1411-2 and a DNA tetrahedral Aptamer 1-AS1411-3. The drug-loaded complex is applied to preparation of drugs for treating melanoma. According to the invention, four dual-targeting DNA nano drug-loaded systems based on CD44 and nucleolin nucleic acid aptamers are constructed, and compared with a single-targeting drug-loaded complex and a negative control group, the four dual-targeting drug-loaded complexes have stronger nuclease degradation resistance, capability of targeting melanoma A375 cells, capability of inhibiting proliferation of the A375 cells and capability of inducing the A375 cells to generate G1 phase retardation..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 30. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SUN LIDAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-11-30, Last update posted on www.tib.eu: 2023-06-08, Last updated: 2023-06-16 |
|---|
| Patentnummer: |
CN113713118 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA012975435 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA012975435 | ||
| 003 | DE-627 | ||
| 005 | 20230616045457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA012975435 | ||
| 035 | |a (EPA)CN113713118 | ||
| 035 | |a (EPA)78684128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SUN LIDAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Establishment and synthesis method of dual-targeting DNA (deoxyribonucleic acid) nano drug-loaded complex |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-11-30, Last update posted on www.tib.eu: 2023-06-08, Last updated: 2023-06-16 | ||
| 520 | |a The invention discloses an establishment and synthesis method of a dual-targeting DNA (deoxyribonucleic acid) nano drug-loaded complex. The drug-loaded complex is prepared by the following steps: simultaneously connecting an Aptamer 1 and a natural AS1411 or a chemically modified AS1411 to a DNA tetrahedron in a manner of complementary base pairing, so as to respectively obtain a DNA tetrahedral Aptamer 1-AS1411, a DNA tetrahedral Aptamer 1-AS1411-1, a DNA tetrahedral Aptamer 1-AS1411-2 and a DNA tetrahedral Aptamer 1-AS1411-3. The drug-loaded complex is applied to preparation of drugs for treating melanoma. According to the invention, four dual-targeting DNA nano drug-loaded systems based on CD44 and nucleolin nucleic acid aptamers are constructed, and compared with a single-targeting drug-loaded complex and a negative control group, the four dual-targeting drug-loaded complexes have stronger nuclease degradation resistance, capability of targeting melanoma A375 cells, capability of inhibiting proliferation of the A375 cells and capability of inducing the A375 cells to generate G1 phase retardation. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a B82Y: Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a phy | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XIE XIAOLAN |4 aut | |
| 700 | 0 | |a LYU FENGJIAO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 30. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78684128/publication/CN113713118A1?q=CN113713118 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 30 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 11 | ||